Single-Cell Measurable Residual Disease Assay for AML

This document is a technical report detailing a novel single-cell measurable residual disease (scMRD) assay developed by Mission Bio for the assessment of acute myeloid leukemia (AML). The report outlines the assay's capability to simultaneously profile DNA mutations and surface immunophenotypes across thousands of individual cells. It compares the results of the scMRD assay with traditional flow cytometry methods, highlighting discrepancies in measurable residual disease (MRD) results. The report presents findings from matched clinical and remission specimens, emphasizing the importance of clonal diversity and its potential as a prognostic biomarker. Additionally, the report discusses the assay's advantages over bulk next-generation sequencing (NGS) and flow cytometry, particularly in resolving genotype-phenotype ambiguities. The document concludes with observations on the correlation between relapse and clonal diversity, suggesting that the assay may identify unique therapeutic targets for AML treatment.